Hemophagocytic Lymphohistiocytosis with Secondary Atrioventricular Block Type II in a Child

Zhongqiang Liu,Hui Guo,Yi Qu,Wei Li,Xihong Li,Dezhi Mu

DOI: https://doi.org/10.1002/pbc.26060

2016-01-01

Pediatric Blood & Cancer

Abstract:To the Editor: An 8-year-old female was admitted to the pediatric intensive care unit with a history of a high fever for 7 days and epistaxis. An ecchymosis (2× 3 cm) was observed on the left knee. Hepatosplenomegaly was present (liver 3 cm, spleen 2 cm below the costal margins). Complete blood count showed white blood cell count 300/mm3, hemoglobin 6.0 g/dl, and platelet count 99,000/mm3. Other abnormal laboratory test results included serum ferritin 16,500 ng/ml, fibrinogen 138 mg/dl, and triglyceride 2.28 mmol/l. Increased hemophagocytosis was evident on a bone marrow aspirate (Figs. 1A and 1B). In addition, measurement of serum Epstein–Barr virus (EBV) DNA was positive at 5.58 × 105 copies/ml. These findings established the diagnosis of EBV-associated hemophagocytic lymphohistiocytosis (HLH).[1] On the second day after admission, the patient felt chest tightness and palpitation before receiving chemotherapy. Electrocardiogram showed second-degree atrioventricular block type II and ST-segment depression (Fig.1C). Echocardiographic tissue Doppler imaging showed normal structure with normal coronary artery diameters. Cardiac troponin was 0.022 μg/l (normal range, 0–0.034 μg/l). The patient was treated with a continuous infusion of isoproterenol hydrochloride and then given a temporary pacemaker under local anesthesia. She responded well to treatment for HLH according to the HLH 2004 protocol,[1] and her cardiac rhythm returned to normal sinus. HLH is a life-threatening clinical syndrome characterized by immune dysregulation, overwhelming immune activation, and inflammation, which is associated with poor prognosis.[2,3] Hypercytokinemia plays an important role in the pathogenesis of EBV–HLH.[4] EBV–HLH combined with a cardiovascular disorder has rarely been reported in the literature. Takeoka et al. reported two cases of Takotsubo cardiomyopathy associated with HLH in adult patients, and concluded that HLH hypercytokinemia may have a role in causing this cardiomyopathy.[5] Otillio et al. reported the first child with HLH-associated Takotsubo cardiomyopathy.[6] Interestingly, Madias argued that the treatment, dopamine and norepinephrine infusion, may have been related to Takotsubo cardiomyopathy in that report.[7] Takotsubo cardiomyopathy is a disorder characterized by transient left ventricular apical wall motion abnormalities associated with emotional or physical stress. The diagnostic criteria also include the absence of obstructive coronary artery disease, new electrocardiographic abnormalities (including atrioventricular block), a modest increase in the cardiac troponin, and the absence of pheochromocytoma and myocarditis.[8] The prognosis of Takotsubo cardiomyopathy is generally favorable, and the clinical symptoms always disappear within 1 month.[9] Our patient, who had no history of heart disease or pheochromocytoma, developed second-degree atrioventricular block type II with normal cardiac troponin and coronary artery size. Furthermore, the arrhythmia resolved 1 month after the severe state of HLH. Thus, we speculate that the emergence of atrioventricular block in the present HLH patient was more likely related to Takotsubo cardiomyopathy.